Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease

The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment

“…In a study comparing patients with alcoholic cirrhosis ( n = 15) and non-alcoholic steatohepatitis (NASH) cirrhosis ( n = 22), patients with NASH cirrhosis had significantly prolonged clot lysis time, indicating a hypofibrinolytic state, in comparison to patients with alcoholic cirrhosis and healthy controls [ 113 ]. This is in accordance with others who also described hypofibrinolysis in patients with NASH [ 114 , 115 ] and cholestatic disease [ 115 ]. Plasma levels of PAI-1 were higher in these two patient groups compared with other aetiologies of cirrhosis and healthy controls.…”

Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction

“…Similarly, liver fibrosis, but not steatosis, was associated with a procoagulant imbalance in chronic hepatitis C patients. 28 However, we could not assess and draw conclusions on the regulation of fibrinolysis, which in a recent study was found impaired in non-diabetic patients with NAFLD, 29 and on the role of neutrophil extracellular traps in triggering coagulation in participants with liver inflammation. 30 Notwithstanding, the present results seem to confirm that subclinical systemic inflammation (CRP levels) impact on the coagulation balance at different levels, 31 even in this cohort of apparently healthy and asymptomatic individuals, but most importantly showed that the association of early liver damage with procoagulant imbalance is independent of CRP.…”

Features of myocardial infarction with ST segment elevation in patients with non-alcoholic liver steatosis and steatohepatitis

“…Доказано, что MPV положительно коррелирует с баллом по шкале SYNTAX и относится к числу предикторов неблагоприятного прогноза при ИМ [26,27]. Другими причинами повышенного тромбообразования при МАЖБП могут служить системная гипекоагуляция и нарушение фибринолиза [28,29].…”